Compare TALK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | FHTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.1M | 360.8M |
| IPO Year | N/A | 2020 |
| Metric | TALK | FHTX |
|---|---|---|
| Price | $3.96 | $6.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $4.88 | ★ $11.43 |
| AVG Volume (30 Days) | ★ 1.4M | 190.1K |
| Earning Date | 02-19-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $214,593,000.00 | $24,518,000.00 |
| Revenue This Year | $23.86 | $40.89 |
| Revenue Next Year | $22.22 | $11.89 |
| P/E Ratio | $157.53 | ★ N/A |
| Revenue Growth | ★ 18.37 | N/A |
| 52 Week Low | $2.22 | $2.95 |
| 52 Week High | $4.36 | $6.95 |
| Indicator | TALK | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.88 | 73.08 |
| Support Level | $3.45 | $4.64 |
| Resistance Level | $4.14 | $5.37 |
| Average True Range (ATR) | 0.15 | 0.41 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 73.19 | 88.10 |
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.